xanomeline
Sign in to saveXanomeline (developmental code name LY-246,708) is a small molecule muscarinic acetylcholine receptor agonist that was synthesized in a collaboration between Eli Lilly and Novo Nordisk as an investigational therapeutic being studied for the treatment of central nervous system (CNS) disorders.
Key facts
- Drug.C
- 14
- Drug.H
- 23
- Drug.image
- Xanomeline.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Xanomeline 3D-Ball-and-Stick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 220
- Drug.routes_of_administration
- Oral
- Drug.class
- Muscarinic acetylcholine receptor agonist
- Drug.ATC_prefix
- None
- Drug.CAS_number
- 131986-45-3
- Drug.PubChem
- 60809
- Drug.IUPHAR_ligand
- 57
- Drug.DrugBank
- DB15357
- Drug.ChemSpiderID
- 54797
- Drug.UNII
- 9ORI6L73CJ
- Drug.KEGG
- D06330
- Drug.ChEBI
- 10056
via Wikipedia infobox
Chemical data
- Formula
- C14H23N3OS
- Molecular weight
- 281.42 g/mol
- IUPAC name
- 3-hexoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
via PubChem
Research
351 papers- Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.JAMA psychiatry · 2024
- Xanomeline.2006
- Xanomeline-trospium (Cobenfy(TM)) for Schizophrenia: A Review of the Literature.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
- Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.Lancet (London, England) · 2024
- Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia.The Annals of pharmacotherapy · 2025
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- +281.156183
Show 1 more fact
- P2868
- muscarinic agonist
via Wikidata · CC0
Article
10 sectionsContents
- Pharmacology
- Pharmacodynamics
- Muscarinic acetylcholine receptor agonist
- Other actions
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Clinical development
- References
- Further reading
Xanomeline (developmental code name LY-246,708) is a small molecule muscarinic acetylcholine receptor agonist that was synthesized in a collaboration between Eli Lilly and Novo Nordisk as an investigational therapeutic being studied for the treatment of central nervous system (CNS) disorders.
Its pharmacological action is mediated primarily through stimulation of central nervous system muscarinic M1 and M4 receptor subtypes. Xanomeline is a non-selective muscarinic acetylcholine receptor agonist with similar high affinity for all five muscarinic acetylcholine receptor subtypes but has greater agonistic activity at the M1 and M4 subtypes.